HC Wainwright Reiterates Buy Rating for Candel Therapeutics (NASDAQ:CADL)

Candel Therapeutics (NASDAQ:CADL)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $11.00 price objective on the stock.

Candel Therapeutics Trading Up 2.2 %

NASDAQ CADL opened at $0.93 on Monday. Candel Therapeutics has a 1 year low of $0.66 and a 1 year high of $3.06. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.37 and a quick ratio of 4.37. The company has a market capitalization of $26.90 million, a PE ratio of -0.85 and a beta of 0.43. The company has a fifty day moving average of $0.98 and a 200 day moving average of $1.21.

Institutional Trading of Candel Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in shares of Candel Therapeutics during the 3rd quarter worth approximately $53,000. Renaissance Technologies LLC acquired a new stake in Candel Therapeutics during the first quarter valued at $28,000. Resources Investment Advisors LLC. purchased a new position in Candel Therapeutics in the first quarter valued at $34,000. BlackRock Inc. increased its holdings in Candel Therapeutics by 19.2% in the first quarter. BlackRock Inc. now owns 46,544 shares of the company’s stock valued at $63,000 after buying an additional 7,497 shares in the last quarter. Finally, Citigroup Inc. acquired a new position in shares of Candel Therapeutics in the second quarter worth about $149,000. Hedge funds and other institutional investors own 18.22% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.